Voya Investment Management LLC Has $3.18 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Voya Investment Management LLC grew its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,870 shares of the company's stock after acquiring an additional 3,520 shares during the period. Voya Investment Management LLC's holdings in BioNTech were worth $3,176,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Daiwa Securities Group Inc. increased its position in BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after buying an additional 128 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after acquiring an additional 150 shares during the period. Midwest Professional Planners LTD. grew its position in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after purchasing an additional 222 shares during the last quarter. Perigon Wealth Management LLC boosted its stake in BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after purchasing an additional 224 shares during the period. Finally, Atomi Financial Group Inc. lifted its holdings in shares of BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after buying an additional 229 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Trading Down 1.4 %

NASDAQ BNTX traded down $1.35 during trading hours on Wednesday, hitting $93.39. 693,093 shares of the company's stock were exchanged, compared to its average volume of 915,631. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $99.87 and a 200 day simple moving average of $109.87. The firm has a market cap of $22.41 billion, a price-to-earnings ratio of -44.48 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. BioNTech's revenue was down 19.5% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on BNTX. Canaccord Genuity Group restated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Morgan Stanley cut their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research report on Tuesday. Truist Financial began coverage on BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 price target on the stock. Citigroup reiterated a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research note on Tuesday. Finally, BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $142.73.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.